Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma

Seminars in Oncology

Volumn 29, Issue 1 SUPPL. 2, 2002, Pages 56-69

  Mangel, Joy ^a   Buckstein, Rena ^a   Imrie, Kevin ^a   Spaner, David ^a   Crump, Michael ^a   Tompkins, Kirsty ^a   Reis, Marciano ^a   Perez Ordonez, Bayardo ^a   Deodhare, Sanjeev ^a   Romans, Robert ^a   Pennell, Nancy ^a   Robinson, Jean B ^a   Hewitt, Karen ^a   Richardson, Patricia ^a   Lima, Ana ^a   Pavlin, Peggy ^a   Berinstein, Neil L ^a  

^a DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CARMUSTINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRUG EFFICACY; DRUG ERUPTION; DRUG MEGADOSE; DRUG SAFETY; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INTERSTITIAL PNEUMONIA; MALE; MANTLE CELL LYMPHOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME; URINARY TRACT INFECTION;

EID: 0036178669     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonc.2002.30143     Document Type: Conference Paper

References (72)

1. New approaches to classifying non-Hodgkin's lymphoma: Clinical features of the major subtypes. Non-Hodgkin's Lymphoma Classification Project
2. Mantle cell lymphoma: A clinicopathologic study of 80 cases
3. Mantle cell lymphoma - An entity comes of age
4. Management of mantle cell lymphoma
5. PRAD-1/cyclin D1 gene overexpression in chronic lymphoproliferative disorders: A highly specific marker of mantle cell lymphoma
6. Bcl-1/cyclin D1 in malignant lymphoma
7. Chromosome t(11;14)(q13;q32) breakpoints in centrocytic lymphoma are highly localized at the bcl-1 major translocation cluster
8. Detection of the chromosomal translocation t(11;14) by polymerase chain reaction in mantle cell lymphomas
9. Failure of immunologic purging in mantle cell lymphoma assessed by polymerase chain reaction detection of minimal residual disease
10. Mantle-cell lymphoma
11. An improved method for detection of B-lymphoid clonality by polymerase chain reaction
12. A clinical analysis of two indolent lymphoma entities: Mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid B-cell subcategories). A Southwest Oncology Group study
13. Efficacy of four different regimens in 64 mantle-cell lymphoma cases: Clinicopathologic comparison with 498 other non-Hodgkin's lymphoma subtypes
14. Multicentre randomized therapeutic trial for advanced centrocytic lymphoma: Anthracycline does not improve prognosis
15. Mantle-cell lymphomas have more widespread disease and a slower response to chemotherapy compared with follicle-center lymphomas: Results of a prospective comparative analysis of the German Low-Grade Lymphoma Study Group
16. Mantle cell lymphoma: Clinical features, treatment and prognosis of 94 patients
17. Patterns of survival in mantle cell lymphoma
18. Mantle cell lymphoma: Presenting features, response to therapy, and prognostic factors
19. Nonfollicular small B-cell lymphomas: A heterogenous group of patients with distinct clinical features and outcome
20. Treatment of mantle-cell lymphomas with the VAD +/- chlorambucil regimen with or without subsequent high-dose therapy and peripheral blood stem-cell transplantation
21. Mantle cell lymphoma. A clinicopathologic study of 68 cases from the Nebraska Lymphoma Study Group
22. The clinical outcome of 65 cases of mantle cell lymphoma initially treated with non-intensive therapy by the British National Lymphoma Investigation Group
23. Mantle cell lymphoma: A retrospective study of 121 cases
24. Which treatment for mantle-cell lymphoma patients in 1998?
25. Management of mantle cell lymphoma
26. Myeloablative therapy with blood stem cell transplantation is effective in mantle cell lymphoma
27. Intensive therapy with peripheral stem cell transplantation in 16 patients with mantle cell lymphoma
28. Sequential high-dose therapy and autologous stem cell transplantation for treatment of mantle cell lymphoma
29. Long-term disease-free survival of patients with advanced mantle-cell lymphoma following high-dose chemotherapy
30. High-dose chemotherapy with hematopoietic stem cell transplantation in patients with mantle cell or diffuse centrocytic non-Hodgkin's lymphomas: A single center experience on 18 patients
31. High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle cell lymphoma: No evidence for long term remission
32. The role of high-dose therapy and autologous hematopoietic stem cell transplantation for mantle cell lymphoma
33. High-dose therapy with stem cell transplantation for mantle cell lymphoma: Results and prognostic factors, a single center experience
34. Autologous stem cell transplantation for mantle cell lymphoma. The experience of the GEL/TAMO Spanish cooperative group
35. Autologous and allogeneic stem cell transplantation for poor-risk mantle cell lymphoma: The City of Hope experience
36. Phase II trial of a salvage therapy by DHAP plus high dose chemotherapy and total body irradiation with autologous stem cell transplantation after failure of CHOP-regimen for mantle cell lymphoma
37. Efficacy of autologous stem cell transplantation in mantle cell lymphoma: A 3-year follow-up study
38. Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: An active regimen for aggressive mantle cell lymphoma
39. The impact of early stem cell transplantation on the prognosis of mantle cell lymphoma
40. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20
41. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study
42. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma
43. IDEC-C2B8 anti-CD20 (rituximab) immunotherapy in patients with low-grade non-Hodgkin's lymphoma and lymphoproliferative disorders: Evaluation of response on 48 patients
44. The effect of rituximab on patients with follicular and mantle-cell lymphoma
45. Treatment of mantle-cell lymphoma with rituximab (chimeric monoclonal anti-CD20 antibody): Analysis of factors associated with response
46. Stem cell function and engraftment is not affected by "in vivo purging" with rituximab for autologous stem cell treatment for patients with low-grade non-Hodgkin's lymphoma
47. In vivo purging with rituximab during stem cell transplantation for indolent lymphoma
48. Mobilization of peripheral stem cells in patients with indolent lymphoma using a combination of MINE with rituximab
49. In vivo depletion of B cells using a combination of high-dose cytosine arabinoside/mitoxantrone and rituximab for autografting in patients with non-Hodgkin's lymphoma
50. Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: Evidence for a role of both chemotherapy and rituximab infusion
51. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphoma
52. Allogeneic hematopoietic transplantation for mantle-cell lymphoma: Molecular remissions and evidence of graft-versus-malignancy
53. Prednimustine, mitoxantrone (PmM) vs. cyclophosphamide, vincristine, prednisone (COP) for the treatment of advanced low-grade non-Hodgkin's lymphomas
54. Multicenter phase II study of fludarabine phosphate for patients with newly diagnosed lymphoplasmacytoid lymphoma, Waldenström's macroglobulinemia, and mantle-cell lymphoma
55. Randomized trial of fludarabine versus fludarabine and idarubicin as front-line treatment in patients with indolent or mantle cell lymphoma
56. NCCTG phase II trial of 2-chlorodeoxyadenosine as initial therapy for mantle cell lymphoma: A well-tolerated treatment with promising activity
57. Phase II trial of fludarabine monophosphate in patients with mantle cell lymphomas
58. Does transplantation improve outcome in mantle cell lymphoma? A study from the EBMT
59. Treatment of resistant mantle cell lymphoma with allogeneic bone marrow transplantation
60. Treatment of follicular and mantle cell non-Hodgkin's lymphoma with anti-CD20 antibody rituximab after high-dose chemotherapy with autologous CD34+ enriched peripheral blood stem cell transplantation
61. Molecular monitoring of minimal residual disease in follicular and mantle cell non-Hodgkin's lymphomas treated with high-dose chemotherapy and peripheral blood progenitor cell autografting
62. Preliminary report of rituximab with intensive chemotherapy for untreated aggressive mantle cell lymphoma
63. Rituxan/CHOP induction therapy in newly diagnosed patients with mantle cell lymphoma
64. Significant prolongation of disease free survival in advanced low grade non Hodgkin lymphomas by interferon alpha maintenance
65. Clinical characteristics and response to chemotherapy of mantle cell lymphomas - Results of a European survey
66. High frequency of molecular remissions associated with rituxan or IFN immunotherapy following ASCT for follicular NHL
67. Further evaluation of a sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation in mantle cell lymphoma
68. Eradication of polymerase chain reaction-detectable chronic lymphocytic leukemia is associated with improved outcome after bone marrow transplantation
69. Eradication of polymerase chain reaction detectable immunoglobulin gene rearrangement in non-Hodgkin's lymphoma is associated with decreased relapse after autologous bone marrow transplantation
70. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma
71. Long term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma
72. High dose therapy with autologous bone marrow support as consolidation of remission in follicular lymphoma: Long term clinical and molecular follow-up